Endocrinology
Conference Coverage
DAPA-CKD resets eGFR floor for safe SGLT2 inhibitor use
Until now, SGLT2 inhibitors were for patients with an eGFR of at least 30 mL/min per m2. New evidence moves the threshold down to 25....
Conference Coverage
Treat-to-target strategy ‘not ready for primetime’ in osteoporosis
Debaters at a session of the recent virtual ASBMR 2020 annual meeting could have gone either way on this topic, but data and evidence are...
Conference Coverage
More dairy lowers risk of falls, fractures in frail elderly
Results from the first randomized trial to show a benefit of dairy food intake on risk of fractures leave it unclear whether it is better to get...
Conference Coverage
Mega vitamin D harms bone in women, not men, without osteoporosis
News
More U.S. states cap insulin cost, but activists will ‘fight harder’
Drugmakers and health insurers have not legally challenged state laws capping out-of-pocket insulin costs; still, such attempts to make insulin...
News
CagA-positive H. pylori patients at higher risk of osteoporosis, fracture
Study adds additional weight to previous findings regarding H. Pylori infection and bone fragility, particularly among CagA-positive...
News
Obesity boosts risks in COVID-19 from diagnosis to death
Excess pounds are linked to excess infection, hospitalization, ICU admission, and mortality.
Conference Coverage
Gut bacteria linked to cardiovascular, other health conditions
“Microbiota and their metabolites ... could serve as potential therapeutic targets for the maintenance of health and prevention and treatment of...
Conference Coverage
DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetes
DAPA-CKD showed that dapagliflozin helps patients with albuminuria and declining eGFR levels whether or not they have type 2 diabetes.
Conference Coverage
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit solidifies class effects